Our essential knowhow is an extensive expertise in the research of human regulatory T cells, their purification from blood products in the clean room and the development of a patented process for the activation of human regulatory T cells.
Through the special manufacturing process of ATreg, we obtain a clinically highly efficient cellular product from leukaphereses that can be made available to patients within 24 hours.


Intellectual Properties

Comprehensive protection rights protect ATreg. This includes the special activation process of Treg, the use of these cells as an ATMP, but also the test systems for the identification of new Treg activating proteins. Some patents have already been granted in the US, Canada, Japan and Europe.
In addition, we received Orphan Drug Designation for treatment in HSCT by EMA and FDA, providing market exclusivity of 7 years in the US and 10 years in the EU upon first market approval.

  • Treg activator GP120 PCT/EP2008/051144 Patent in EU, USA, Canada and Japan, NBE-Patent in Japan, USA and EU
  • Biomarker for diagnostic of ATreg patients PCT/EP2015/0180501 in EU, USA
Orphan Drug Designations
  • EU (EMA/ODD/159/17)
  • USA (DRU-2017-6135)

ActiTrexx GmbH
Langenbeckstr. 1, Building 401
55131 Mainz, Germany

Handelsregisternummer HRB 49910 
Ust.-ID DE335671604

>> Pioniergeist-Preisverleihung 2022>> Press Release Financing>> Press Release SPD>> SWR

ActiTrexx presentation (coming soon)
Financial Reports (coming soon)